Clinical Trial Update: A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating vonapanitase (PRT-201) administered after AVF creation in CKD patients has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• vonapanitase (vonapanitase)

Snippet

Sponsor: Proteon Therapeutics | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-08-13